Basic Research on Novel Anticoagulant Therapy during VV-ECMO Focusing on Anti-inflammatory Effects of Hydrogen

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K17896
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55060:Emergency medicine-related
• Research Institution: Okayama University
• Principal Investigator: Nojima Tsuyoshi 岡山大学, 医歯薬学域, 助教 (60869717)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 水素 / VV-ECMO / 抗凝固療法

Outline of Final Research Achievements

The purpose of this study was to develop a novel anticoagulant therapy using hydrogen in VV-ECMO using LPS rats, focusing on the anti-inflammatory effects of hydrogen. In this study, we investigated whether hydrogen can enhance anticoagulant effects in ECMO. Hydrogen decreased mRNA expression of inflammatory cytokines IL-6 and IL-1β, but HO-1 was not significantly different in the hydrogen group. Furthermore, PAI-1 mRNA expression related to anticoagulation was not significantly different in the hydrogen group, although PAI-1 expression was decreased in the hydrogen group, and chemokines such as E-selectin and CCL2 were not significantly different. From this study, it is possible that hydrogen may have anticoagulant effects, but significant differences were not clarified.

Free Research Field

救命救急

Academic Significance and Societal Importance of the Research Achievements

VV-ECMOでは、治療中の出血が問題となる。VV-ECMOでは回路内での血液凝固を防ぐために抗凝固薬を使用するが、さらに出血リスクが高くなってしまう。また、感染症では炎症により出血の危険性がさらに高くなるため、出血傾向を防ぐことが死亡率軽減につながると考えられた。そのため、VV-ECMO中に抗炎症作用を有する水素を用いることで抗凝固薬の減量が可能であるかを検討した。今回の検討では、水素を用いることによる抗炎症作用は有意差を持って確認できたが、抗凝固作用に関しては、その作用を有するものの、有意差を持って確認はできなかった。今後も研究を続けていく必要があると考えられる。